Skip to content

IAS: Low rates of HIV transmission in breastfeeding women on ART

IAS: ART interruption particularly unsafe for HIV-positive patients coinfected with hepatitis B or C

IAS: Integrase inhibitor raltegravir (MK-0518) potent, durable and more tolerable than efavirenz in treatment-naive at 48 weeks

IAS: Regular viral load testing essential for patients in resource limited settings on NNRTIs, says US resistance expert

IAS: Hepatitis C clusters reveal international transmission among HIV-positive gay men

IAS: Novel once-daily CCR5 antagonist, INC9471, appears potent, well tolerated after 14 days monotherapy

IAS: Aciclovir treatment doesn't significantly reduce HIV or HSV-2 shedding in genital secretions

IAS: Vicriviroc still effective at 48 weeks in treatment-experienced, but relationship with cancer remains uncertain

IAS: Studies present reassuring data on the use of ART in patients on TB treatment